Harrow In Sharp Focus: This Fast-Growing Pharma Stock Just Got Cheaper

About this episode

This episode discusses the investment potential of Harrow, a pharma company, following a recent stock drop despite strong growth prospects.

Healthcare investing isn't always about blockbuster drugs – sometimes the best opportunities hide in profitable niches. In this episode, we sit down with Finimize analyst Russell Burns to dig into Harrow, an ophthalmology pharma company whose stock has dropped 30% in recent weeks despite a still-strong growth outlook. With shares up 400% over five years – dwarfing the S&P 500 – Russell explains why this pullback might be the entry point investors have been waiting for. Try Finimize ...

People in this episode

Host: Finimize

Guest: Russell Burns

Topics covered

• healthcare investing
• ophthalmology
• pharma stocks
• investment opportunities
• market analysis

Keywords

• Harrow
• ophthalmology
• pharma stock
• investment
• Russell Burns
• S&P 500
• growth outlook
• market pullback

Mentioned in this episode

Organizations: Harrow, S&P 500

More episodes of Investor Intelligence

• Is Crypto A Safe Haven? w/ Chris Bendiksen, Bitcoin Research Lead (Coinshares) · June 4, 2026 · 32 min
• Eight Stocks You Could Invest In If The Strait Of Hormuz Reopens · May 27, 2026 · 15 min
• Why This Cable Giant Could Be The Smartest Way To Play AI And Power · May 20, 2026 · 17 min
• Should You Invest In SpaceX’s IPO? · May 14, 2026 · 44 min
• How Our Investing Ideas Have Help Up: May 2026 · May 6, 2026 · 28 min
• Why Did Elliot Management Just Make A Billion-Dollar Bet On An Air-Conditioner Maker? · April 29, 2026 · 20 min